 |
|
|
| |
Prevalence and Impact of Baseline NS5A Resistance-Associated
Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR)
Against GT1a Infection - 16 Weeks vs 12 weeks
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 13-17 San Francisco
Jacobson IM1; Asante-Appiah E2; Wong P2; Black T2; Howe A2; Wahl J2; Robertson MN2; Nguyen B-Y2;
Shaughnessy M2; Hwang P2; Barr E2; Hazuda D2
1Mount Sinai Beth Israel, New York, NY, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
